Scitara Corp. raises $15m in Series B Financing to disrupt the laboratory data integration market
Summary
Led by existing investor Northpond Ventures (https://northpondventures.com/), with participation from Flybridge Capital and experienced financial advisors to the biopharma and life science tools industry, the funding will springboard Scitaras ambitious growth plans for 2022 and beyond to solve the laboratory data integration challenge.Scitaras growth has been fuelled by the introduction of its industry leading category Scientific Integration Platform™ SIP™, a cloud native infrastructure that allows scientific laboratories to realize the full benefits of digital transformation. As life science and pharma industries come under monumental pressure to deliver breakthroughs at accelerated speeds, the importance of accurate data custodianship in real time has never been more critical. Scitara SIP integrates scientific data across the enterprise, and in tandem with artificial intelligence (AI) and analytics tools, scientists are provided new insights to drive faster decision making, and information to help accelerate products to market. "Scitara SIP powered by our Digital Lab Exchange™ DLX™ platform brings a breakthrough level of laboratory automation, and is designed to fully comply with the most stringent requirements of regulated markets. "Chip Hazard, General Partner at Flybridge commented on the deal: "With an impressive list of strategic partners that include leading instrument, informatics, and global service organizations, and a growing list of diverse customers, including some of the worlds largest pharmaceutical companies, vaccine manufacturers, and cutting-edge biotechnology players, Scitara is leading the next generation of digital transformation in the lab.